SNGX News and Press, Soligenix Inc. From 03/30/21

Soligenix (SNGX): FY GAAP EPS of -$0.64 misses by $0.10.Revenue of $2.4M (-47.8% Y/Y) beats by $0.2M.Shares +4.03% PM.Press Release For further details see: Soligenix EPS misses by $0.10, beats on revenue

Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results PR Newswire PRINCETON, N.J. , March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developin...

New York, New York--(Newsfile Corp. - March 16, 2021) - PCG Digital -- The future is looking bright at Soligenix, Inc. In a corporate update released on February 24 th , Dr. Christopher Schaber, Chairman, President and CEO, updated investors on the status of ongoing research projects. The re...

Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PR Newswire PRINCETON, N.J. , March 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph...

3 Penny Stocks To Watch Even During This Pullback While the last few weeks have been up and down for penny stocks, investors seem hopeful about the future. As we witness the natural ebb and flow of the stock market, there are a few things to be excited about in the coming months. For on...

Gainers: Five Prime Therapeutics (FPRX) +78%, Ampio Pharmaceuticals (AMPE) +10%, Soligenix (SNGX) +7%.Losers: BioVie (BIVI) -29%, Schrodinger (SDGR) -25%, KemPharm (KMPH) -19%, Anchiano Therapeutics (ANCN) -15%, AbCellera Biologics (...

Soligenix, Inc. (SNGX) has added ~13.7% in the pre-market after announcing the publication of pre-clinical immunogenicity studies for CiVax, the company’s heat-stable vaccine candidate for the prevention of COVID-19.According to the company, the article posted as an...

Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine - Broad and potent immune responses demonstrated with full length Spike protein antigen - Large animal studies and COVID variant testing planned - Facilitates development of a h...

Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter PR Newswire PRINCETON, N.J. , Feb. 24, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focus...

New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SNGX) is fast approaching a new drug application (NDA) submission and potential FDA approval f...